One of the co-founders of InflaRx, Nicolas Fulpius has served as Chairman of the Board since its inception in 2007. Long active in the venture capital field between the US and Europe, for the Lombard Odier Immunology fund, for Ultreia Capital and as Partner at Affentranger Associates, Nicolas has become an entrepreneur at heart: he created, developed and helped finance several companies in the Biotech and ICT field for which he acts as CEO or as Director. Mr. Fulpius recently sold Veltigroup, one of the largest Swiss ICT service providers, to Swisscom. Since, Nicolas Fulpius holds the role of Chief Digital Officer of Swisscom Enterprise Customers, and is a member of the Swisscom Ventures investment committee.
Nicolas recently relocated to the Silicon Valley to explore opportunities to promote Swiss-based innovations for global go-to-market. Nicolas Fulpius holds an MBA from the University of St. Gallen, Switzerland, and a Masters in Science in Engineering from Stanford University, USA.
Ms. Ma has been a director on our board since September 2016. Ms. Ma has been the Vice President and Secretary of the board of Staidson (Beijing) BioPharmaceuticals Co., Ltd. since June 2012, the chairman of the board of Beijing Defengrei Biotechnology Co. Ltd since September 2015, the Company Secretary of Staidson BioPharma Inc., in California, since 2013 and the Chief Executive Officer of Staidson Hong Kong Investment Company Limited, in Hong Kong, since 2015. In previous roles, she has served as the General Manager and Securities Affair Representative of Staidson (Beijing) BioPharmaceuticals Co., Ltd. from 2009 to 2012, in JOINN Laboratories (Beijing) from 2002 to 2009, and in the China Medical Association Telemedicine Consultation Center from 2000 to 2001. Ms. Ma holds a bachelor’s degree from Hunan Medical University in China and an MBA from HKU SPACE Community College.
Ms. Uschmann joined our board as a director and deputy chairwoman in 2007. She has served as an Investment Manager at beteiligungsmanagement thüringen gmbh since 1999. Prior to joining beteiligungsmanagement thüringen gmbh, Ms. Uschmann served in various roles at several banks, such as Credit Analyst and Corporate Relationship Manager at Bayerische Vereinsbank AG and at Thüringer Aufbaubank, and taught Economics at Fachhochschule in Gotha, Germany. She has served on the boards of eZono AG since 2007, where she was the board’s deputy chairwoman from 2009 to 2010, and chairwoman since 2010, and of Preventicus GmbH since 2014. Ms. Uschmann previously served on the board of AST Advanced Shockwave Technology Inc., from 2011 until 2017. She holds a skilled worker degree and an MBA from Fachhochschule (University of Applied Financial Sciences), as well as a degree in project management from GPM Deutsche Gesellschaft für Projektmanagement.
Mr. Kubler has served as a director on our board since 2015. Mr. Kubler has been a partner with the GIG Ltd., a venture capital advisory firm with offices in Switzerland and Malta, since 2012. He previously served on the boards of WWM AG and Jobydu AG, each based in Switzerland. Mr. Kubler was a managing director and corporate secretary of a private equity holding company from 2003 to 2010. Before 2003, he held various roles in international investment banks and boutiques. Mr. Kubler has a master’s degree in business and economics, as well as a master’s degree in law from the University of St. Gallen, in Switzerland.
Mr. Holstein currently serves as Chief Financial Officer of MorphoSys AG, a dual-listed (Frankfurt and Nasdaq) drug development company. He joined MorphoSys in 2011 from Fresenius, a global healthcare company, where he served as Regional CFO for the Europe/Middle East region of Fresenius Kabi AG, and as Managing Director of Fresenius Kabi Deutschland GmbH. Over his nearly 16 years at Fresenius, Mr. Holstein held a variety of financial and general management positions, including Regional CFO of Fresenius Kabi Asia Pacific Ltd., Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary, Wittgensteiner Kliniken AG. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry in Frankfurt and London. He holds a Diploma in Business Administration from the University of Muenster.
Richard Brudnick currently serves as Chief Business Officer and Head of Strategy for Codiak BioSciences, a leader in the field of exosome therapeutics. Prior to joining Codiak, Mr. Brudnick was Executive Vice President of Business Development and Alliance Management at Bioverativ, Inc., a company he helped found in 2016. Prior to Bioverativ’s acquisition by Sanofi in March 2018, Mr. Brudnick led business development efforts to build a significant pipeline in rare blood disorders, including an acquisition, a multi-product collaboration and additional scientific collaborations and licenses. Mr. Brudnick joined Bioverativ at its spin-off from Biogen where, over the course of nearly 15 years, he initiated, led and completed transactions that now include several of the company’s marketed products and late-stage pipeline, including Tecfidera, Spinraza and its biosimilars joint venture with Samsung. Mr. Brudnick also was CEO of a regional pharmaceutical distribution business, which he sold to a strategic buyer; co-founded two companies; and was a strategy consultant at Bain & Company.
Prof. Niels C. Riedemann, M.D., Ph.D.
Chief Executive Officer and Founder
Prof. Riedemann received his medical training at Freiburg, Germany, and Stanford University, USA. He performed basic science research at The University of Michigan in the field of complement immunology and inflammation for several years and then completed his board certification in General Surgery at Hannover Medical School, where he still holds a Professorship in Experimental Surgery. He specialized as an Intensive Care Physician and was appointed Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany. His research has been awarded with several national and international awards, including the Hugo-Schottmüller-Award and Hans-Liniger-Award. He has received extensive extra-mural funding and published over 50 high impact scientific publications. He serves as a member on two Boards of Directors of large scientific governmental programs. As Founder of InflaRx, Prof. Riedemann combines in-depth basic science experience and advanced clinical knowledge in the field of inflammation and acute care. Prof. Riedemann has lead InflaRx as CEO since 2007.
Prof. Renfeng Guo, M.D.
Chief Scientific Officer and Founder
Prof. Renfeng Guo received his M.D. degree from Norman Bethune Medical School in China. He did his post-doctoral research training in the laboratory of Prof. Peter Ward at the University of Michigan, Ann Arbor. He has been a junior and senior faculty member at the University of Michigan since 2001, where he remains an Adjunct Research Associate Professor. He has authored or co-authored over 75 high impact publications in the fields of cancer, infection, and inflammation research. He holds an Adjunct Professorship at Beijing Institute of Microbiology and Epidemiology, since 2008. As Founder and CSO of InflaRx, Prof. Guo leverages his expertise in antibody research and inflammation, bringing together a highly efficient research team for drug development and building a focused pipeline based on their cutting-edge technology. Prof. Guo has been heading scientific development at InflaRx as the full-time CSO since its inception, in 2007.